These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 12243733)

  • 21. Long synthetic peptides encompassing the Plasmodium falciparum LSA3 are the target of human B and T cells and are potent inducers of B helper, T helper and cytolytic T cell responses in mice.
    Perlaza BL; Sauzet JP; Balde AT; Brahimi K; Tall A; Corradin G; Druilhe P
    Eur J Immunol; 2001 Jul; 31(7):2200-9. PubMed ID: 11449374
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Copolymer adjuvants in malaria vaccine development.
    Hunter RL; Lal AA
    Am J Trop Med Hyg; 1994; 50(4 Suppl):52-8. PubMed ID: 8172332
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effect of context and adjuvant on the immunogenicity of recombinant proteins and peptide conjugates derived from the polymorphic malarial surface antigen MSA2.
    Jones GL; Spencer L; Lord R; Saul AJ
    Vaccine; 1996 Jan; 14(1):77-84. PubMed ID: 8821653
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Strain-transcending immune response generated by chimeras of the malaria vaccine candidate merozoite surface protein 2.
    Krishnarjuna B; Andrew D; MacRaild CA; Morales RA; Beeson JG; Anders RF; Richards JS; Norton RS
    Sci Rep; 2016 Feb; 6():20613. PubMed ID: 26865062
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Human immune response in Plasmodium falciparum malaria. Synthetic peptides corresponding to known epitopes of the Pf155/RESA antigen induce production of parasite-specific antibodies in vitro.
    Chougnet C; Troye-Blomberg M; Deloron P; Kabilan L; Lepers JP; Savel J; Perlmann P
    J Immunol; 1991 Oct; 147(7):2295-301. PubMed ID: 1717554
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Improving the malaria transmission-blocking activity of a Plasmodium falciparum 48/45 based vaccine antigen by SpyTag/SpyCatcher mediated virus-like display.
    Singh SK; Thrane S; Janitzek CM; Nielsen MA; Theander TG; Theisen M; Salanti A; Sander AF
    Vaccine; 2017 Jun; 35(30):3726-3732. PubMed ID: 28578824
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Immunogenicity of recombinant BCG-based vaccine expressing the 22 kDa of serine repeat antigen (SE22) of Plasmodium falciparum.
    Teo WH; Nurul AA; Norazmi MN
    Trop Biomed; 2012 Jun; 29(2):239-53. PubMed ID: 22735846
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Malaria vaccine candidate: design of a multivalent subunit α-helical coiled coil poly-epitope.
    Olugbile S; Villard V; Bertholet S; Jafarshad A; Kulangara C; Roussilhon C; Frank G; Agak GW; Felger I; Nebie I; Konate K; Kajava AV; Schuck P; Druilhe P; Spertini F; Corradin G
    Vaccine; 2011 Sep; 29(40):7090-9. PubMed ID: 21803099
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Evaluation of immune responses elicited in mice against a recombinant malaria vaccine based on Plasmodium vivax Duffy binding protein.
    Yazdani SS; Shakri AR; Mukherjee P; Baniwal SK; Chitnis CE
    Vaccine; 2004 Sep; 22(27-28):3727-37. PubMed ID: 15315853
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Immune responses in congenic mice to multiple antigen peptides based on defined epitopes from the malaria antigen Pf332.
    Ahlborg N; Andersson R; Perlmann P; Berzins K
    Immunology; 1996 Aug; 88(4):630-5. PubMed ID: 8881768
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Immunogenicity of the Plasmodium falciparum asexual blood-stage synthetic peptide vaccine SPf66.
    Millet P; Campbell GH; Sulzer AJ; Grady KK; Pohl J; Aikawa M; Collins WE
    Am J Trop Med Hyg; 1993 Mar; 48(3):424-31. PubMed ID: 7682382
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Influence of adjuvants on murine immune responses against the C-terminal 19 kDa fragment of Plasmodium vivax merozoite surface protein-1 (MSP-1).
    Yang C; Collins WE; Xiao L; Patterson PS; Reed RC; Hunter RL; Kaslow DC; Lal AA
    Parasite Immunol; 1996 Nov; 18(11):547-58. PubMed ID: 9226693
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Synthetic oligodeoxynucleotides containing CpG motifs enhance immunogenicity of a peptide malaria vaccine in Aotus monkeys.
    Jones TR; Obaldia N; Gramzinski RA; Charoenvit Y; Kolodny N; Kitov S; Davis HL; Krieg AM; Hoffman SL
    Vaccine; 1999 Aug; 17(23-24):3065-71. PubMed ID: 10462241
    [TBL] [Abstract][Full Text] [Related]  

  • 34. T-cell epitopes in Pf155/RESA, a major candidate for a Plasmodium falciparum malaria vaccine.
    Kabilan L; Troye-Blomberg M; Perlmann H; Andersson G; Högh B; Petersen E; Björkman A; Perlmann P
    Proc Natl Acad Sci U S A; 1988 Aug; 85(15):5659-63. PubMed ID: 2456577
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Irradiated sporozoite vaccine induces HLA-B8-restricted cytotoxic T lymphocyte responses against two overlapping epitopes of the Plasmodium falciparum sporozoite surface protein 2.
    Wizel B; Houghten RA; Parker KC; Coligan JE; Church P; Gordon DM; Ballou WR; Hoffman SL
    J Exp Med; 1995 Nov; 182(5):1435-45. PubMed ID: 7595214
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Evaluation of a new fusion antigen, cd loop and HAP2-GCS1 domain (cd-HAP) of Plasmodium falciparum Generative Cell Specific 1 antigen formulated with various adjuvants, as a transmission blocking vaccine.
    Pourhashem Z; Nourani L; Sani JJ; Yousefi H; Pirahmadi S; Sabouri M; Raz A; Djadid ND; Zakeri S; Mehrizi AA
    Malar J; 2023 Dec; 22(1):374. PubMed ID: 38071314
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A totally synthetic polyoxime malaria vaccine containing Plasmodium falciparum B cell and universal T cell epitopes elicits immune responses in volunteers of diverse HLA types.
    Nardin EH; Calvo-Calle JM; Oliveira GA; Nussenzweig RS; Schneider M; Tiercy JM; Loutan L; Hochstrasser D; Rose K
    J Immunol; 2001 Jan; 166(1):481-9. PubMed ID: 11123327
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Conversion of poorly immunogenic malaria repeat sequences into a highly immunogenic vaccine candidate.
    Milich DR; Hughes J; Jones J; Sällberg M; Phillips TR
    Vaccine; 2001 Dec; 20(5-6):771-88. PubMed ID: 11738741
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Induction of sustained and elevated immune responses to weakly immunogenic synthetic malarial peptides by encapsulation in biodegradable polymer microspheres.
    Men Y; Gander B; Merkle HP; Corradin G
    Vaccine; 1996 Oct; 14(15):1442-50. PubMed ID: 8994320
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Nasal immunization with a malaria transmission-blocking vaccine candidate, Pfs25, induces complete protective immunity in mice against field isolates of Plasmodium falciparum.
    Arakawa T; Komesu A; Otsuki H; Sattabongkot J; Udomsangpetch R; Matsumoto Y; Tsuji N; Wu Y; Torii M; Tsuboi T
    Infect Immun; 2005 Nov; 73(11):7375-80. PubMed ID: 16239536
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.